Novartis Takes On Colombia Over Glivec Pricing
Novartis is taking Colombian authorities to court over moves to cut the price of its anticancer Glivec (imatinib) and warns that the intellectual property rights of other products are under threat. Companies selling hepatitis C drugs should pay attention as their products could be next to face similar measures.
You may also be interested in...
The EU is once again facing criticism for its pursuit of investor-state dispute settlement-like mechanisms.
Civil society groups are calling for Colombian authorities to repeal a controversial decree that they say will make compulsory licensing harder and which would prevent declarations of public interest from being used to lower drug prices.
AFIDRO, the association representing Colombia’s research-based pharmaceutical industry, is taking the government to court over new pricing regulations that follow the controversial declaration of public interest for Novartis’ Glivec (imatinib).